GLPG Galapagos NV ADR

This article analyzes Galapagos Nv (GLPG) by providing key findings, institutional trading strategies, and multi-timeframe signal analysis. It highlights a strong near-term sentiment potentially leading to a long-term positive bias, alongside an exceptional short setup targeting an 8.2% downside with a 0.3% risk. The AI models offer distinct trading strategies for various risk profiles, including position, momentum breakout, and risk hedging.

Raymond James has reiterated its Market Perform rating on Galapagos NV following mixed results from two Phase 2 studies of its TYK2 inhibitor GLPG3667, despite the company appearing undervalued according to InvestingPro Fair Value metrics. While one study showed positive results in dermatomyositis, another failed to meet statistical significance in systemic lupus erythematosus, leading Raymond James to suggest partnering the asset. This news comes after Galapagos reported a larger-than-expected loss in Q3 2025 earnings and Bernstein SocGen Group initiated coverage with a Market Perform rating.

Raymond James has reiterated its Market Perform rating on Galapagos NV (NASDAQ:GLPG) after mixed Phase 2 trial results for its TYK2 inhibitor GLPG3667. While one study in dermatomyositis showed positive results, another in systemic lupus erythematosus did not meet statistical significance. The company's Q3 2025 earnings also showed a larger-than-expected loss, though the stock has remained steady.

Raymond James has reiterated its Market Perform rating on Galapagos NV following mixed results from two Phase 2 studies of its experimental drug GLPG3667. Despite positive data in dermatomyositis, the firm expressed limited enthusiasm, suggesting partnering the asset would be beneficial. The company also reported a larger-than-expected loss in Q3 2025, yet its stock has remained steady.

Raymond James has maintained its Market Perform rating on Galapagos NV following mixed Phase 2 study results for its TYK2 inhibitor GLPG3667. While positive data was observed in dermatomyositis, the study for systemic lupus erythematosus did not meet statistical significance. Despite these results and a larger-than-expected Q3 2025 loss, Galapagos's stock has remained steady.

Galapagos NV (GLPG) announced that its phase 3 trial for the TYK2 inhibitor, GLPG3667, successfully met its primary endpoint in treating dermatomyositis, an autoimmune disease, demonstrating significant clinical benefits. However, a separate phase 3 trial for lupus did not meet its primary endpoint, leading Galapagos to explore strategic partnerships for its dermatomyositis treatment. Despite the positive dermatomyositis results, the company's shares fell approximately 3.6% in after-hours trading.